# Keen Vision Acquisition Corp.

Keen Vision Acquisition Corp. is an other based in Summit, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Summit, United States
- **Region:** North America
- **Address:** Summit, NJ, United States
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** keenvc.com

## Regulatory record

- **Reports private funds:** No

## About

Keen Vision Acquisition Corp. was formed in 2021 by Chairman and CEO Kenneth Lam, filing with the SEC the following year to raise $150 million through an initial public offering of 15 million units. The vehicle closed in July 2022, debuting on Nasdaq under the symbol KVAC. Lam, a veteran of cross-border Asia-Pacific investment banking, assembled a board that included his son Alex Lam and CFO David Kaye, positioning the SPAC to bridge Asian innovation with U.S. public markets. The SPAC's mandate targeted biotechnology and healthcare services companies, specifically those with a nexus to Asia. Lam's sourcing network emphasized Taiwan, Hong Kong, and mainland China, where early-stage biotechs often lack clear paths to Nasdaq liquidity. In February 2024, Keen Vision announced a definitive agreement to merge with Acepodia, a clinical-stage cell therapy company based in Alameda, California, with R&D operations in Taipei (per the firm, February 2024). Acepodia's pipeline includes antibody-cell conjugation therapies for solid tumors, reflecting the precision oncology focus Lam had scoped in the original S-1. The trust raised $150 million in its IPO, with an additional over-allotment option providing flexibility during redemption windows. No concurrent PIPE was announced alongside the Acepodia de-SPAC, a structure typically sensitive to sponsor capital commitments. Lam's prior board roles at Nasdaq-listed companies including MDH Acquisition Corp. The combined entity was expected to trade on Nasdaq post-close. The ACEPODIA transaction exemplifies a structural pattern — a U.S.-domiciled SPAC with Asian sponsor DNA targeting a biotech issuer with dual U.S.-Asia operations. This cross-border architecture differs from mainland China-backed SPACs that have faced CFIUS and audit-inspection scrutiny. Lam's regulatory path relied on Taiwanese and U.S. corporate domiciles, avoiding PCAOB-eligibility complications that stalled competing de-SPACs from mainland China targets.

## Sectors

- Biotechnology
- Healthcare Services

## People

- Kenneth K.H. Lam — Chairman and Chief Executive Officer
- Alex L.K. Lam — Director
- David M. Kaye — Chief Financial Officer

## Questions

### Who runs Keen Vision Acquisition Corp.?

Kenneth Lam serves as Chairman and CEO. He brings a background in cross-border investment banking with a focus on Asia-Pacific capital markets. His son Alex Lam is listed as a director, and David Kaye serves as CFO. The management team reflects a family-linked governance model common among smaller SPAC sponsors.

### Has Keen Vision completed a de-SPAC transaction?

Yes. In February 2024, Keen Vision announced a definitive merger agreement with Acepodia, a privately held biotechnology company developing antibody-cell conjugation therapies. The transaction was structured as a standard de-SPAC with no concurrent PIPE disclosed at announcement. Post-close, the combined company was to remain Nasdaq-listed.

### What differentiated Keen Vision's SPAC structure from generalist peers?

Keen Vision launched with a sector-concentrated mandate — biotechnology and healthcare — in a SPAC market dominated by generalists. Its Asia-U.S. cross-border structure avoided the PCAOB audit-inspection risks that affected SPACs targeting mainland China-based operating companies. The Acepodia combination exemplified this: a U.S.-domiciled biotech with R&D operations in Taiwan, where audit regulators faced fewer compliance barriers.

### Is Keen Vision still active after the Acepodia merger?

Keen Vision Acquisition Corp. was a single-purpose SPAC designed to dissolve upon completion of its initial business combination. Following the February 2024 Acepodia deal announcement, the vehicle was expected to close and delist, with Kenneth Lam transitioning to a board role at the combined company per standard de-SPAC practice. No subsequent SPAC filings from the Lam group have been publicly reported.

## Related profiles

- [IMMUTEP Ltd](https://altss.com/profile/immutep-ltd)
- [Daxor Corp](https://altss.com/profile/daxor-corp)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/keen-vision-acquisition-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology